DESIGN THERAPEUTICS INC. - COMMON STOCK

5,0000

04-октября-24 15:59:57

15 мин. задержка

Акции

+0,2800

+5,93%

Сегодняшний диапазон

4,7000 - 5,0200

ISIN

N/A

Источник

NASDAQ

Design Therapeutics to Participate in the 2024 Cantor Global Healthcare Conference

10 сен 2024 08:00:00 Источник Nasdaq GlobeNewswire
Design Therapeutics Announces Second Quarter 2024 Financial Results and Reviews Near-term Milestones for GeneTAC™ Portfolio

05 авг 2024 08:00:00 Источник Nasdaq GlobeNewswire
Design Therapeutics Announces First Quarter 2024 Financial Results and Highlights Upcoming Program Milestones

08 май 2024 16:05:01 Источник Nasdaq GlobeNewswire
Design Therapeutics to Participate in the 2024 RBC Capital Markets Global Healthcare Conference

07 май 2024 06:30:00 Источник Nasdaq GlobeNewswire
Design Therapeutics Outlines Progress Across GeneTAC™ Platform and Announces Fourth Quarter and Full Year 2023 Financial Results

19 мар 2024 16:01:00 Источник Nasdaq GlobeNewswire
Design Therapeutics to Webcast Fourth Quarter and Full Year 2023 Financial Results and Comprehensive Portfolio Update

12 мар 2024 06:30:00 Источник Nasdaq GlobeNewswire
Design Therapeutics Reports Third Quarter 2023 Financial Results and Plans for a Comprehensive Portfolio Update in Early 2024

13 ноя 2023 16:05:00 Источник Nasdaq GlobeNewswire
Design Therapeutics Provides Pipeline Update and Reports Second Quarter 2023 Financial Results

14 авг 2023 16:05:00 Источник Nasdaq GlobeNewswire
Design Therapeutics Reports Initial Results from Phase 1 Multiple-Ascending Dose Study of DT-216 for the Treatment of Friedrich Ataxia

14 авг 2023 16:01:00 Источник Nasdaq GlobeNewswire
Design Therapeutics to Present at the 2023 Jefferies Healthcare Conference

31 май 2023 06:30:00 Источник Nasdaq GlobeNewswire
Design Therapeutics Provides Pipeline Updates and Reports First Quarter 2023 Financial Results

09 май 2023 16:05:01 Источник Nasdaq GlobeNewswire
Design Therapeutics to Present Preclinical Data on its GeneTAC™ Small Molecule, DT-168, for the Treatment of Fuchs Endothelial Corneal Dystrophy at ARVO 2023

24 апр 2023 06:30:00 Источник Nasdaq GlobeNewswire
Design Therapeutics Highlights Pipeline Progress and Reports Fourth Quarter and Full Year 2022 Financial Results

14 мар 2023 16:05:00 Источник Nasdaq GlobeNewswire
Design Therapeutics to Participate in the SVB Securities Virtual Global Biopharma Conference

08 фев 2023 06:30:00 Источник Nasdaq GlobeNewswire
Design Therapeutics Reports Positive Data from Single-Ascending Dose Trial of DT-216 for the Treatment of Friedreich Ataxia and Portfolio Progress

07 дек 2022 16:01:00 Источник Nasdaq GlobeNewswire
Design Therapeutics Highlights Pipeline Progress and Upcoming Milestones and Reports Third Quarter 2022 Financial Results

03 ноя 2022 16:05:02 Источник Nasdaq GlobeNewswire
Design Therapeutics to Present Preclinical Data Highlighting the Potential of its GeneTAC™ Small Molecule, DT-216, for the Treatment of Friedreich Ataxia at ICAR 2022

17 окт 2022 16:05:00 Источник Nasdaq GlobeNewswire
Design Therapeutics to Present at the 2022 Jefferies Cell and Genetic Medicine Summit

22 сен 2022 06:30:00 Источник Nasdaq GlobeNewswire
Design Therapeutics Highlights Upcoming Milestones and Reports Second Quarter 2022 Financial Results

08 авг 2022 16:05:01 Источник Nasdaq GlobeNewswire
Design Therapeutics to Participate in the 2022 Wedbush PacGrow Virtual Healthcare Conference

03 авг 2022 06:30:00 Источник Nasdaq GlobeNewswire

<<
<
1
>

Принимаю NetDania's website uses cookies. By continuing browsing our website, you agree to our Правила в отношении Cookies, Политика конфиденциальности and Правила и условия.